Compare iShares MBS ETF (MBB) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MBS ETF vs Stryker Corporation — how do they compare? iShares MBS ETF trades at $93.58, while Stryker Corporation trades at $316.25 (market cap $122.35B). The key difference: Stryker Corporation pays a 1% dividend while iShares MBS ETF pays none, and Stryker Corporation is trading nearer its 52-week high, iShares MBS ETF nearer its low. Which is the better fit depends on your goals.
| MBB | SYK | |
|---|---|---|
52-Week High | $96.91 | $403.53 |
52-Week Low | $92.92 | $282.58 |
Market Cap | — | $122.35B |
Sector | — | Technology |
Enterprise Value | — | $134.10B |
Dividend Yield | — | 1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MBB (iShares MBS ETF) trades at $93.57, down 0.22% on the day, with a bearish technical signal from moving averages. The ETF shows neutral oscillator readings and has upcoming dividend payments. Recent news highlights institutional activity, including Comerica Bank reducing its stake while Concurrent Investment Advisors and Aureum Wealth increased positions in Q4 2026.
The outlook remains cautious due to bearish technical trends and mixed institutional sentiment. Risks include interest rate sensitivity impacting mortgage-backed securities. Opportunities lie in steady dividend income, but investors should monitor Federal Reserve policy shifts for potential volatility in the MBS market.
Stryker (SYK) trades at $319.14, down 0.23% on the day, with a bearish technical signal despite strong fundamentals. The company reported $25.12B revenue and $3.25B net income for 2025, maintaining robust profitability with 63.83% gross margins and 13.21% net margins. Recent Q1 2026 earnings missed expectations due to a cybersecurity disruption, but management maintained full-year guidance. Analyst consensus remains strongly bullish with a $388.44 price target and 74% buy ratings.
The stock presents a compelling opportunity for long-term investors given its strong fundamentals and innovation pipeline, though near-term technical weakness and competitive pressures warrant caution. Upside potential exists from continued Mako robotics adoption and market share gains, while risks include cybersecurity vulnerabilities and integration challenges from acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
